Table 5.
Positive HPV6, 11, and 18 serology and HNSCC risk (restricted to HPV16-negative subjects)
| Serology | Controls, n (%) | Pharynx |
Oral |
||||
| Cases, n (%) | Crude OR (95% CI) | Adjusted OR (95% CI)a | Cases, n (%) | Crude OR (95% CI) | Adjusted OR (95% CI)a | ||
| HPV6 | |||||||
| Negative | 429 (88%) | 83 (80%) | 1.0 | 1.0 | 134 (83%) | 1.0 | 1.0 |
| Positive | 61 (12%) | 21 (20%) | 1.8 (1.0–3.1) | 1.4 (0.8–2.6) | 28 (17%) | 1.5 (0.9–2.4) | 1.2 (0.7–2.0) |
| HPV6b | |||||||
| Negative | 429 (88%) | 83 (80%) | 1.0 | 1.0 | 134 (83%) | 1.0 | 1.0 |
| Low titer | 35 (7%) | 7 (7%) | 1.0 (0.4–2.4) | 0.8 (0.3–2.0) | 9 (6%) | 0.8 (0.4–1.8) | 0.7 (0.3–1.5) |
| High titer | 26 (5%) | 14 (13%) | 2.8 (1.4–5.6) | 2.3 (1.1–4.8) | 19 (12%) | 2.3 (1.3–4.4) | 1.9 (1.0–3.6) |
| HPV11 | |||||||
| Negative | 468 (96%) | 97 (93%) | 1.0 | 1.0 | 154 (95%) | 1.0 | 1.0 |
| Positive | 22 (4%) | 7 (7%) | 1.5 (0.6–3.7) | 1.3 (0.5–3.4) | 8 (5%) | 1.1 (0.5–2.5) | 0.9 (0.4–2.1) |
| HPV11b | |||||||
| Negative | 468 (96%) | 97 (93%) | 1.0 | 1.0 | 154 (95%) | 1.0 | 1.0 |
| Low titer | 10 (2%) | 5 (5%) | 2.4 (0.8–7.2) | 2.0 (0.6–6.6) | 3 (2%) | 0.9 (0.2–3.4) | 0.7 (0.2–2.7) |
| High titer | 12 (2%) | 2 (2%) | 0.8 (0.2–3.7) | 0.7 (0.1–3.5) | 5 (3%) | 1.3 (0.4–3.7) | 1.1 (0.4–3.2) |
| HPV18 | |||||||
| Negative | 456 (93%) | 94 (90%) | 1.0 | 1.0 | 154 (95%) | 1.0 | 1.0 |
| Positive | 34 (7%) | 10 (10%) | 1.4 (0.7–3.0) | 1.3 (0.6–2.9) | 8 (5%) | 0.7 (0.3–1.5) | 0.7 (0.3–1.5) |
| HPV18b | |||||||
| Negative | 456 (93%) | 94 (90%) | 1.0 | 1.0 | 154 (95%) | 1.0 | 1.0 |
| Low titer | 17 (3%) | 5 (5%) | 1.4 (0.5–4.0) | 1.3 (0.4–3.8) | 4 (2%) | 0.7 (0.2–2.1) | 0.7 (0.2–2.2) |
| High titer | 17 (3%) | 5 (5%) | 1.4 (0.5–4.0) | 1.3 (0.5–4.0) | 4 (2%) | 0.7 (0.2–2.1) | 0.6 (0.2–1.9) |
Bold typeface indicates P < 0.05.
a
Cases and controls matched for age and gender; adjusted models controlled for smoking and drinking.
b
Low and high titer categories determined using median positive titer value as cut point.